Nushmia Z. Khokhar

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

George D. Demetri, Margaret von Mehren, Robin L. Jones et al. · Journal of Clinical Oncology · 2015 · 834 citations · Full text

Medicine, Oncology, Pharmacology +17

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari, Attaya Suvannasankha, Joseph W. Fay et al. · Blood · 2017 · 443 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

Shaun Cordoba, Shimobi Onuoha, Simon Thomas et al. · Nature Medicine · 2021 · 272 citations · Full text

Medicine, Hematology, Oncology +17

Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Meletios Α. Dimopoulos, Jesús F. San Miguel, Andrew R. Belch et al. · Haematologica · 2018 · 210 citations · Full text

Medicine, Oncology, Pharmacotherapy +16